Search for Clinical Trial Results

Sponsored By

Liposarcoma - 29 Studies Found

Status Study
Active, not recruiting Study Name: Brostallicin Clinical Trial for Myxoid Liposarcoma
Condition: Myxoid Liposarcoma
Date: 2008-03-03
Interventions: Drug: Brostallicin Patients will receive Brostallicin administered intravenously (IV) over 10 minutes at
Recruiting Study Name: Ph II Cabazitaxel DD Liposarcoma
Condition: Dedifferentiated Liposarcoma
Date: 2013-07-30
Interventions:
  • Drug: Cabazitaxel Other Name:

Recruiting Study Name: Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma
Condition: Liposarcoma
Date: 2015-01-05
Interventions:
  • Drug: HDM201
  • Drug: LEE011
Recruiting Study Name: Selinexor in Advanced Liposarcoma
Condition: Dedifferentiated Liposarcoma
Date: 2015-10-13
Interventions:
  • Drug: Selinexor Selinexor 60mg
Completed Study Name: Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
Condition: Liposarcoma,Myxoid
Date: 2007-12-20
Interventions:
  • Drug: Trabectedin Trabectedin

Recruiting Study Name: Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
Condition: Liposarcoma
Date: 2014-09-24
Interventions: Drug: efatutazone Given PO
Recruiting Study Name: Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas
Condition: Myxoid Liposarcoma of Soft Tissue
Date: 2014-03-06
Interventions: Radiation: dose reduction of preoperative radiotherapy in MLS A: The primary sarcoma in case of non-meta
Completed Study Name: Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
Condition:
  • Liposarcoma
  • Surgically Unresectable Lipos
    Date: 2012-01-06
    Interventions: Drug: pazopanib Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administ
Recruiting Study Name: MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas
Condition:
  • Liposarcoma
  • Metastatic Liposarcoma
    Date: 2016-11-29
    Interventions: Drug: MGCD516 Administered at 150 mg orally, daily, in continuous 21 day cycles. An orally available, po
Withdrawn Study Name: Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
Condition: Dedifferentiated Liposarcoma
Date: 2009-09-01
Interventions: Drug: IPI-504 IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatmen
Next >>>